Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa dose-escalation study of BRII-179 (VBI-2601) in chronic hepatitis B
CTR20200603Phase 2Completed
- Sponsor
- Brii Biosciences
- Start
- Apr 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of BRII-179 in Chronic Hepatitis B (CHB) (3 arms), sponsored by Brii Biosciences. Primary endpoints: Incidence of adverse events and serious adverse events and Clinical laboratory and other safety assessments. Started Apr 2020; status: completed.
02
Drugs
BRII-179
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20200603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200603.